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Chloroquine urea derivatives: synthesis and antitumor 
activity in vitro
In the current paper, we describe the design, synthesis and 
antiproliferative screening of novel chloroquine deriva-
tives with a quinoline core linked to a hydroxy or halogen 
amine through a flexible aminobutyl chain and urea spacer. 
Synthetic pathway leading to chloroquine urea derivatives 
4–10 includes two crucial steps: i) synthesis of chloroquine 
benzotriazolide 3 and ii) formation of urea derivatives 
through the reaction of compound 3 with the corresponding 
amine. Testing of antiproliferative activity against four 
 human cancer cell lines revealed that chloroquine urea 
 derivatives 9 and 10 with aromatic moieties show activity 
at micromolar concentrations. Therefore, these molecules 
represent interesting lead compounds that might provide 
an insight into the design of new anticancer agents.
Keywords: chloroquine, hydroxychloroquine, urea, antitumor 
activity in vitro
Chloroquine and its related drug, hydroxychloroquine, are antimalarial agents active 
against the asexual form of Plasmodium inside red blood cells (1). They are members of the 
4-substituted quinoline drug class, along with mefloquine, amodiaquine and the parent 
drug quinine. Chloroquine and hydroxychloroquine interfere with the biosynthesis of 
nucleic acids in Plasmodium and inhibit heme polymerase that converts toxic heme, a prod-
uct of hemoglobin decomposition caused by a parasite, into non-toxic hemozoin, resulting 
in the accumulation of heme within the parasite (2). Anticancer properties of these drugs 
are also well documented; they affect the Toll-like receptor 9, p53 and CXCR4-CXCL12 
pathway in cancer cells, tumor vasculature and immune system, augment TRAIL-induced 
apoptosis and induce G2/M phase arrest in human cancer cells (3, 4). Scientific evidence 
also supports the use of chloroquine and hydroxychloroquine in combination with con-
ventional anticancer drugs (3, 5–8). Their chemosensitizing and radiosensitizing activities 
have been confirmed in over 30 clinical studies with different cancer types and in combi-
nation with various anticancer treatments. It has been confirmed that chloroquine and 
hydroxychloroquine inhibit autophagy, a cellular recycling system, involving lysosomal 
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reoxygenation and tumor exposure to chemotherapeutic agents and radiation (9–11). Tar-
geting autophagy can overcome BRAF inhibitor resistance mechanisms in autophagy-
-dependent tumors, e.g., in brain tumors. Mulcahy Levy et al. (12) reported successful treat-
ment of a patient with chloroquine after failure of the BRAFV600E inhibitor vemura fenib. 
However, organs in which autophagy plays a homeostatic role may be sensitive to the 
combined use of chloroquine and anticancer drugs (13).
Due to the above mentioned facts, derivatization of chloroquine has been in the focus 
of many researchers worldwide. Numerous chloroquine derivatives have been prepared 
in order to overcome Plasmodium resistance, the main problem in malaria treatment (see, 
for example, refs. 14–16) or in finding new anticancer agents (refs. 17–20). In this paper, we 
report on the design and synthesis of chloroquine derivatives with potential antiprolife-
rative properties. Our novel compounds are composed of the quinoline core, aminobutyl 
chain and hydroxy or halogenamine moiety bound by the urea spacer. The rationale for 
the design of these compounds is supported by the fact that quinoline and amino alcohol 
pharmacophores are present in several antimalarial drugs (quinine, mefloquine, lumefan-
trine, halofantrine) (21), while urea motif is crucial in several kinase inhibitors, a subclass 
of antitumor agents (sorafenib, regorafenib) (22). The two here described compounds are 
organofluoro derivatives. It is known that approximately 20 % of currently approved 
drugs contain one or more fluorine atoms: fluoro derivatives have increased stability, 
 selectivity and/or membrane permeability compared to their nonfluorinated analogs, so 




Melting points were measured on a Stuart Melting Point (SMP3) apparatus (Barlo-
world Scientific, UK) in open capillaries with uncorrected values. A CEM Discover micro-
wave reactor was used for microwave reactions (CEM GmbH, Germany). IR spectra were 
recorded on a Paragon 500 (PerkinElmer, UK) FT-IR spectrophotometer and UV-Vis spec-
tra on a Lambda 20 double beam spectrophotometer (PerkinElmer). 1H and 13C NMR spec-
tra were recorded at 25 °C on an NMR Avance 600 spectrometer (Bruker, Germany). Chem-
ical shifts (δ) are reported in parts per million (ppm) relative to tetramethylsilane in the 1H 
spectra and to dimethyl sulfoxide (DMSO) residual peak as reference in the 13C spectra 
(39.52 ppm). Coupling constants (J) are reported in Hertz (Hz). Mass spectra were collected 
on an HPLC-MS/MS instrument (HPLC, Agilent Technologies 1200 Series; MS, Agilent 
Technologies 6410 Triple Quad, USA). Mass determination was realized using electron 
spray ionization (ESI) in positive mode. Elemental analyses were performed on a CHNS 
LECO analyzer (LECO Corporation, USA). All compounds were routinely checked by TLC 
with Merck silica gel 60F-254 glass plates using an appropriate mobile phase (Merck, Ger-
many). Spots were visualized by short-wave UV light and iodine vapour. Column chroma-
tography was performed on silica gel 60 (0.063–0.200 mm) as the stationary phase.
All chemicals and solvents were of analytical grade and were purchased from com-
mercial sources. Triphosgene, butane-1,4-diamine, 4,7-dichloroquinoline, 4-(chlorophenyl)
(phenyl)methanamine hydrochloride,  triethylamine (TEA) and (3-(4,5-dimethylthiazol-
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2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (USA), 
(1-aminocyclopropyl)methanol hydrochloride, (1-aminocyclobutyl)methanol, (1R,3S)-
3-aminocyclopentanol hydrochloride, 2-amino-4-fluorobutan-1-ol, 3-amino-1,1,1-trifluoro-
propan-2-ol hydrochloride from Enamine (Ukraine), while 4-(2-aminoethyl)phenol (tyra-
mine) and benzotriazole were purchased from Alfa Aesar (Thermo Fisher Scientific, USA). 
Anhydrous solvents were dried and redistilled prior to use.
Syntheses
N1-(7-chloroquinolin-4-yl)butane-1,4-diamine (1). – A mixture of 4,7-dichloroquinoline 
(0.396 g, 0.002 mol) and 1,4-diaminobutane (1.763 g, 0.02 mol) was stirred under microwave 
irradiation (300 W) at 95 °C. After 60 min, the reaction mixture was diluted with dichloro-
methane, extracted with 5 % NaOH (4 × 40 mL) and washed with water (2 × 40 mL). Or-
ganic layer was dried over anhydrous sodium sulfate, filtered and evaporated under re-
duced pressure to give 0.531 g (90 %) of white solid 1 (24).
1-Benzotriazole carboxylic acid chloride (BtcCl, 2). – 1-Benzotriazole carboxylic acid chlo-
ride (2) was prepared from benzotriazole and triphosgene according to the previously 
published procedure (25).
N-{4-[(7-chloroquinolin-4-yl)amino]butyl}-1H-1,2,3-benzotriazole-1-carboxamide (3). – To a 
cold solution (0 °C) of BtcCl (0.363 g, 0.002 mol) and TEA (0.202 g, 0.002 mol) in dry toluene 
(5 mL), a suspension of compound 1 (0.5 g, 0.002 mol) in dry dioxane (8 mL) was added drop-
wise. The reaction mixture was stirred at room temperature for 1 h. Solvent was evaporated 
under reduced pressure. The crude product was purified by column chromatography (di-
chloromethane/methanol 9:1) and triturated with ether to give white solid 3 (0.663 g, 84 %).
1-{4-[(7-Chloroquinolin-4-yl)amino]butyl}-3-[1-(hydroxymethyl)cyclopropyl]urea (4). – A 
mixture of compound 3 (0.158 g, 0.0004 mol), (1-aminocyclopropyl)methanol hydrochlo-
ride (0.099g, 0.0008 mol), TEA (0.162 g, 0.0016 mol) and sodium dithionite (0.002 g) in di-
chloromethane (2 mL) was stirred under microwave irradiation (300 W) at 65 °C. After 20 
min, the solvent was evaporated under reduced pressure; the residue was dissolved in 
ethyl acetate and extracted with 5 % NaOH solution (3 × 15 mL) and water (2 × 15 mL). The 
product started to precipitate from the organic layer, which was then vacuum filtered. The 
organic layer was evaporated under reduced pressure and combined with the residue after 
filtration. The white solid (0.113 g, 78 %) was collected after trituration with ether.
1-{4-[(7-Chloroquinolin-4-yl)amino]butyl}-3-[1-(hydroxymethyl)cyclobutyl]urea (5). – A 
mixture of compound 3 (0.158 g, 0.0004 mol), (1-aminocyclobutyl)methanol (0.081 g, 0.0008 
mol), TEA (0.081 g, 0.0008 mol) and sodium dithionite (0.002 g) in dichloromethane (2 mL) 
was stirred under microwave irradiation (300 W) at 65 °C. After 20 min, the solvent was 
evaporated under reduced pressure. The residue was dissolved in ethyl acetate and ex-
tracted with 5 % NaOH solution (3 × 15 mL) and water (2 × 15 mL), dried over anhydrous 
sodium sulfate and evaporated. The yellow solid (0.082 g, 54 %) was collected after tritura-
tion with ether.
1-{4-[(7-Chloroquinolin-4-yl)amino]butyl}-3-[(1R,3S)-3-hydroxycyclopentyl]urea (6). – A 
mixture of compound 3 (0.158 g, 0.0004 mol), (1R,3S)-3-aminocyclopentane-1-ol hydro-
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chloride (0.110 g, 0.0008 mol), TEA (0.162 g, 0.0016 mol) and sodium dithionite (0.002 g) in 
dichloromethane (2 mL) was stirred under microwave irradiation (300 W) at 65 °C. After 
30 min, the solvent was evaporated under reduced pressure. The residue was dissolved 
in ethyl acetate and extracted with 5 % NaOH solution (3 × 15 mL) and water (2 × 15 mL), 
dried over anhydrous sodium sulfate and evaporated. After purification by column chro-
matography (cyclohexane/ ethyl acetate/ methanol 1:1:0.75), yellow oil (0.102 g, 68 %) was 
obtained.
1-{4-[(7-Chloroquinolin-4-yl)amino]butyl}-3-(4-fluoro-1-hydroxybutan-2-yl)urea (7). – A 
mixture of compound 3 (0.158 g, 0.0004 mol), 2-amino-4-fluorobutane-1-ol (0.086 g, 0.0008 
mol), TEA (0.081 g, 0.0008 mol) and sodium dithionite (0.002 g) in dichloromethane (2 mL) 
was stirred under microwave irradiation (300 W) at 65 °C. After 40 min, the solvent was 
evaporated under reduced pressure. After two consequent triturations with water and 
ether, a white solid was obtained (0.123 g, 80 %).
1-{4-[(7-Chloroquinolin-4-yl)amino]butyl}-3-(3,3,3-trifluoro-2-hydroxypropyl)urea (8). – A 
mixture of compound 3 (0.158 g, 0.0004 mol), 3-amino-1,1,1-trifluoropropane-2-ol hydro-
chloride (0.132 g, 0.0008 mol), TEA (0.162 g, 0.0016 mol) and sodium dithionite (0.002 g) in 
dichloromethane (2 mL) was stirred under microwave irradiation (300 W) at 65 °C. After 
30 min, the solvent was evaporated under reduced pressure; the residue was dissolved in 
ethyl acetate and extracted with 5 % NaOH solution (3 × 15 mL) and water (2 × 15 mL), dried 
over anhydrous sodium sulfate and evaporated. The white solid (0.118 g, 73 %) was col-
lected after trituration with ether.
1-{4-[(7-Chloroquinolin-4-yl)amino]butyl}-3-(4-hydroxyphenethyl)urea (9). – A mixture of 
compound 3 (0.158 g, 0.0004 mol), 4-(2-aminoethyl)phenol (0.110 g, 0.0008 mol), TEA (0.081 
g, 0.0008 mol) and sodium dithionite (0.002 g) in dichloromethane (2 mL) was stirred under 
microwave irradiation (300 W) at 65 °C. After 40 min, the solvent was evaporated under 
reduced pressure. After purification by column chromatography (dichloromethane/meth-
anol 9.5:0.5) and trituration with ether, a pale yellow solid (0.149 g, 90 %) was obtained.
1-[(4-Chlorophenyl)(phenyl)methyl)-3-{4-[(7-chloroquinolin-4-yl)amino]butyl}urea (10). – A 
mixture of compound 3 (0.158 g, 0.0004 mol), (4-chlorophenyl)(phenyl)methanamine hy-
drochloride (0.203 g, 0.0008 mol), TEA (0.162 g, 0.0016 mol) and sodium dithionite (0.002 g) 
in dichloromethane (2 mL) was stirred under microwave irradiation (300 W) at 65 °C. After 
40 min, the solvent was evaporated under reduced pressure. The residue was dissolved in 
ethyl acetate and extracted with 5 % NaOH solution (3 × 15 mL). The product started to 
precipitate from the organic layer, which was then vacuum filtered. The organic layer was 
evaporated under reduced pressure and combined with the residue after filtration. The 
white solid (0.093 g, 47 %) was collected after trituration with ether.
Cell viability assay
HCT 116 (colon carcinoma), MCF-7 (breast adenocarcinoma), H 460 (lung carcinoma) 
and SW 620 (colon carcinoma) cells (American Type Culture Collection, ATCC, USA) were 
cultured as monolayers and maintained in Dulbecco’s modified Eagle medium (DMEM), 
supplemented with 10 % fetal bovine serum (FBS), 2 mmol L–1 L-glutamine, 100 U mL–1 
penicillin and 100 μg mL–1 streptomycin in a humidified atmosphere with 5 % CO2 at 37 °C. 
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The growth inhibition activity was assessed as described previously (26, 27). Briefly, the 
cells were seeded into standard 96-well microtiter plates on day 0. Cell concentrations were 
adjusted according to the cell population doubling time (PDT): 3000 cells per well for 
HCT116 and SW 620 cell lines (PDT = 20–24 h) and 4,000 cells per well for MCF-7 cell lines 
(PDT = 33 h). Afterwards, the tested compounds were added into five consecutive 10-fold 
dilutions (10–8 to 10–4 mol L–1) and incubated for further 72 h. Working dilutions were fresh-
ly prepared on the day of testing. The solvent (DMSO) was also tested for the possible in-
hibitory activity by adjusting its concentration to be the same as in working concentrations 
(maximum concentration of DMSO was 0.25 %). After 72 h of incubation, the cell growth 
rate was evaluated by performing the MTT assay that detects dehydrogenase activity in 
viable cells. The absorbance was measured on a microplate reader at 570 nm. Each test point 
was performed in quadruplicate in at least three individual experiments. The results are 
expressed as IC50, which is the concentration necessary for 50 % of inhibition. The IC50 val-
ues for each compound were calculated from dose-response curves using linear regression 
analysis, using FORCAST function in Excel, by fitting the test concentrations that give PG 
(percentage of growth) values above and below the reference value (i.e., 50 %). Each result 
is the  mean value from three separate experiments.
RESULTS AND DISCUSSION
The novel chloroquine derivatives 4–10 were prepared by a simple two-step method, 
which includes synthesis of benzotriazolide 3 and its aminolysis with the corresponding 
amine: (1-aminocyclopropyl)methanol, (1-aminocyclobutyl)methanol, (1R, 3S)-3-aminocy-
clopentanol, 2-amino-4-fluorobutan-1-ol, 3-amino-1,1,1-trifluoropropan-2-ol, 4-(2-amino-
ethyl)phenol (tyramine) or 4-(chlorophenyl)(phenyl)methanamine). The following reaction 
step was carried out in a microwave reactor in the presence of TEA. Compound 3 was 
prepared by acylation of chloroquine derivative 1 with 1-benzotriazole carboxylic acid 
chloride (2), while the starting compounds 1 and 2 were prepared from commercially 
available 4,7-dichloroquinoline and butane-1,4-diamine (24), and benzotriazole and tri-
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Purification of compounds was carried out using crystallization methods and/or col-
umn chromatography. Yields for urea derivatives 4–10  ranged  from 47 to 90 %. Structures 
of new compounds 4–10 were confirmed by IR, 1H and 13C NMR spectra. All spectral data 
are given in Table I. Enumeration of  atoms is presented in Fig. 1.
Quinoline hydrogen atoms at positions 10, 15, 12, 14 and 9 in 1H NMR spectra ap-
peared as doublets at d 8.41-8.35, 8.35-8.26, 7.80-7.76, 7.49-7.40 and 6.54-6.45 ppm, resp. Two 
NH groups in the spacer at positions 2 and 7 appeared as triplets at d 7.65-7.31 and 6.07-5.91 
ppm, while the position of OH groups ranged from 6.15 and 3.45 ppm (all signals D2O 
exchangeable). Quinoline carbon atoms in 13C spectra were located in the aromatic region 
and gave the appropriate atom count. Carbonyl C-atom gave a signal between 158.84 and 
157.21 ppm. In addition, the presence of a carbonyl functional group was indicated by the 
appearance of two strong stretching vibration bands in IR spectra at 1660–1613 and 1590–
1579 cm–1. The carbonyl group in benzotriazolide 3 was shifted to higher wavenumbers 
(1736 and 1577 cm–1) and lower ppm values (149.02). The signal of carbon atom 2’ in product 
10 bearing two phenyl residues showed up at d 6.88-6.85 ppm (doublet, 1H NMR) and 56.26 
ppm (13C NMR), resp. Phenyl and benzhydryl residues in urea derivatives 9 and 10 gave 
the expected signals in the aromatic region and appropriate hydrogen/carbon count. Car-
bon atom 4’ in urea 8 with three fluorine atoms and the neighboring atom 3’ gave quartets 
with the coupling constants of 283.76 and 28.35 Hz, resp. Chemical structure of new com-
pounds was also supported by CHN analysis and mass spectroscopy. Molecular ion peaks 
corresponding to the expected molecular formulas were obtained for all compounds. m/z 
data and the expected relative molecular masses are given in Table I, while NMR and mass 
spectra are collected in Supplementary Material.
Drug-like properties of novel CQ-derivatives were calculated using the Chemicalize.
org program (28). A common set of physicochemical parameters was calculated: number 
of atoms, molecular weight (Mr), partition coefficient (log P), number of H-bond donors 
(HBD), number of H-bond acceptors (HBA), molar refractivity (MR) and topological polar 
surface area (TPSA). These parameters are presented in Table II. All compounds (except 
compound 10, which showed minimal aberration in log P) are fully in agreement with 
Lipinski’s and Gelovani’s rules for prospective small molecular drugs (number of atoms 
20–70, Mr ≤ 500, log P ≤ 5, number of HBD ≤ 5, number of HBA ≤ 10, MR within the range 
of 40 and 130 cm3 mol–1, TPSA < 140 Å2).



































































































Fig. 1. Atom enumeration of compounds 3–10 in NMR spectra.
477

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































K. Pavić et al.: Chloroquine urea derivatives: synthesis and antitumor activity in vitro, Acta Pharm. 68 (2018) 471–483.
 
Antiproliferative activity
Antiproliferative activity was tested on four human tumor cell lines (HCT 116, MCF-7, 
H 460 and SW 620) utilizing a standard MTT assay. Standard anticancer drug etoposide 
(Eto) was used as the positive control. The results are summarized in Table III.
The results showed that chloroquine urea 9 and 10 with aromatic moieties were the 
most active compounds, while the ureas derived from cyclic amino alcohols (compounds 
Table II. Drug-like properties of novel CQ-derivatives (28)
Compd. Molecular formula
Number 







4 C18H23ClN4O2 48 362.86 1.40 4 4 4 98.85 86.28
5 C19H25ClN4O2 51 376.89 1.84 4 4 4 103.45 86.28
6 C19H25ClN4O2 51 376.89 1.59 4 4 4 103.49 86.28
7 C18H24ClFN4O2 50 382.86 1.33 4 4 4 100.88 86.28
8 C17H20ClF3N4O2 47 404.82 2.02 4 4 4 96.87 86.28
9 C22H25ClN4O2 54 412.92 3.41 4 4 4 116.80 86.28
10 C27H26Cl2N4O 60 493.43 5.81 3 3 3 139.16 66.05
HBD – H-bond donor; HBA – H-bond acceptor; MR – molar refractivity; TPSA – topological polar surface area
a Out of four.
Table III. Antiproliferative activity of compounds 4–10
Compd. Structure
IC50 (μmol L–1)a









































≥ 100 77 ± 25 ≥ 100 60 ± 27
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4–6) or aliphatic amines bearing hydroxyl group and one or three fluorine atoms (com-
pounds 7 and 8) showed low activity or were practically inactive. Urea 10 showed activity 
at low micromolar concentrations, with IC50 value of 2 μmol L–1 towards all tested cancer 
cell lines, while IC50 value of urea 9 was 5–8 times higher, depending on the cell line. Nev-
ertheless, along with compound 8 it exhibited activity comparable to that of etoposide 
against cell line SW 620.
CONCLUSIONS
In summary, we have developed a practical and efficient route for the synthesis of 
chloroquine urea derivatives. The drug-likeness study showed promising bioactivity 
scores for the new compounds. Preliminary screening revealed that two hits, namely, 
1-{4-[(7-chloroquinolin-4-yl)amino]butyl}-3-(4-hydroxyphenethyl)urea (9) and 1-[(4-chloro-
phenyl)(phenyl)methyl)-3-{4-[(7-chloroquinolin-4-yl)amino]butyl}urea (10), showed sig-
nificant antiproliferative effects in vitro against all of the tested cancer cell lines. The dif-
ferences in activity between analogues differing only in the urea region highlighted the 
need for further work with other substituents.
Acknowledgments. – The study was supported by the Croatian Science Foundation (research proj-
ects IP-2014-09-1501 and IP-2013-5660) and University of Zagreb (support for 2017). 
Supplementary Material is available upon request.
Abbreviations, acronyms, symbols. – BtH, benzotriazole; DMEM, Dulbecco’s modified Eagle’s me-
dium; Eto, etoposide; H 460, lung carcinoma cell line; HBA, H-bond acceptor; HBD, H-bond donor; 
HCT 116, colorectal carcinoma cell line; FBS, fetal bovine serum; IC50 , concentration that causes 50 % 
growth inhibition; log P, partition coefficient; MCF-7, breast adenocarcinoma cell line; MR, molar 
refractivity; MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PDT, cell popula-
tion doubling time; PG, percentage of growth; SW 620, colon carcinoma cell line; TEA, triethylamine; 






























2 ± 0.04 2 ± 0.2 2 ± 0.2 2 ± 0.01
Eto 5 ± 2 1 ± 0.7 0.1 ± 0.04 20 ± 4
Eto – etoposide; a IC50 – the concentration that causes 50 % growth inhibition.
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